

acid modification at position K392 selected from K392F, K392L and K392M.

**54.** The isolated heteromultimer according to claim **53**, wherein the amino acid modification at position T366 is T366I or T366L.

**55.** The isolated heteromultimer according to claim **53**, wherein the amino acid modification at position K392 is K392L or K392M.

**56.** The isolated heteromultimer according to claim **37**, wherein:

- (a) the first CH3 domain polypeptide further comprises the amino acid modification S400E; or
- (b) the second CH3 domain polypeptide further comprises the amino acid modification N390R; or
- (c) the first CH3 domain polypeptide further comprises the amino acid modification S400E and the second CH3 domain polypeptide further comprises the amino acid modification N390R.

**57.** The isolated heteromultimer according to claim **37**, wherein:

- (a) the first CH3 domain polypeptide further comprises the amino acid modification S400R; or
- (b) the second CH3 domain polypeptide further comprises the amino acid modification N390D or N390E; or
- (c) the first CH3 domain polypeptide further comprises the amino acid modification S400R and the second CH3 domain polypeptide further comprises the amino acid modification N390D or N390E.

**58.** The isolated heteromultimer according to claim **37**, wherein the IgG is IgG1.

**59.** The isolated heteromultimer according to claim **58**, wherein the IgG1 is a human IgG1.

**60.** The isolated heteromultimer according to claim **37**, wherein the heteromultimer is a bispecific antibody or a multispecific antibody.

**61.** The isolated heteromultimer according to claim **37**, wherein the heteromultimer comprises at least one antigen-binding domain.

**62.** The isolated heteromultimer according to claim **61**, wherein the antigen-binding domain binds a cancer antigen.

\* \* \* \* \*